Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Operating Leases (2020 - 2025)

IGC Pharma has reported Operating Leases over the past 6 years, most recently at $5000.0 for Q3 2025.

  • Quarterly Operating Leases fell 85.71% to $5000.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $5000.0 through Sep 2025, down 85.71% year-over-year, with the annual reading at $10000.0 for FY2025, 95.19% down from the prior year.
  • Operating Leases was $5000.0 for Q3 2025 at IGC Pharma, down from $7000.0 in the prior quarter.
  • Over five years, Operating Leases peaked at $433000.0 in Q2 2021 and troughed at $5000.0 in Q3 2025.
  • The 5-year median for Operating Leases is $207000.0 (2023), against an average of $198631.6.
  • Year-over-year, Operating Leases increased 0.48% in 2024 and then plummeted 95.19% in 2025.
  • A 5-year view of Operating Leases shows it stood at $374000.0 in 2021, then tumbled by 35.56% to $241000.0 in 2022, then plummeted by 52.28% to $115000.0 in 2023, then crashed by 89.57% to $12000.0 in 2024, then tumbled by 58.33% to $5000.0 in 2025.
  • Per Business Quant, the three most recent readings for IGC's Operating Leases are $5000.0 (Q3 2025), $7000.0 (Q2 2025), and $10000.0 (Q1 2025).